%0 Journal Article %T Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors. %+ Centre de recherche %+ Department of Medicine, University of Montreal %+ Caprion [Montréal] %+ Institut Armand Frappier (INRS-IAF) %+ Department of Medicine (UBC - St Paul Hospital) %+ Clinique Médicale Quartier Latin [Montréal] %+ Clinique Médicale l'Actuel %+ McGill University Health Center [Montreal] (MUHC) %A El-Far, Mohamed %A Kouassi, Pascale %A Sylla, Mohamed %A Zhang, Yuwei %A Fouda, Ahmed %A Fabre, Thomas %A Goulet, Jean-Philippe %A van Grevenynghe, Julien %A Lee, Terry %A Singer, Joel %A Harris, Marianne %A Baril, Jean-Guy %A Trottier, Benoit %A Ancuta, Petronela %A Routy, Jean-Pierre %A Bernard, Nicole %A Tremblay, Cécile L %Z We would like first to thank all the study participants for their generous collaboration. We thank the Montreal Primary HIV infection cohort (directed by Dr Jean-Pierre Routy) for providing access to primary infected samples. Thanks to Mr Mario Legault and Réseau SIDA/MI du FRQ-S for the continuous support. We would like to thank Ms Stéphanie Matte, Mme Tsoarello Mabanga, Mme Xiaoyan Ni, Dr Olfa Debbeche and Mme Véronique Lafontaine for their valuable help with the preparation of the cohort lists and patient samples. Thanks also for Sonia Deschênes for her careful reading of the manuscript. Thanks for the financial and technical support provided by the Canadian Trial Network (CTN). Dr Cécile Tremblay is Director of the Pfizer/University of Montreal Chair on Translational HIV Research and a scholar from the Fonds de Recherche en Santé du Québec. Mohamed El-Far had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis %< avec comité de lecture %@ 2045-2322 %J Scientific Reports %I Nature Publishing Group %V 6 %P 22902 %8 2016 %D 2016 %R 10.1038/srep22902 %M 26978598 %K Chronic inflammation %K HIV infections %Z Life Sciences [q-bio] %Z Life Sciences [q-bio]/ImmunologyJournal articles %X HIV-infected slow progressors (SP) represent a heterogeneous group of subjects who spontaneously control HIV infection without treatment for several years while showing moderate signs of disease progression. Under conditions that remain poorly understood, a subgroup of these subjects experience failure of spontaneous immunological and virological control. Here we determined the frequency of SP subjects who showed loss of HIV control within our Canadian Cohort of HIV(+) Slow Progressors and identified the proinflammatory cytokine IL-32 as a robust biomarker for control failure. Plasmatic levels of the proinflammatory isoforms of IL-32 (mainly β and γ) at earlier clinic visits positively correlated with the decline of CD4 T-cell counts, increased viral load, lower CD4/CD8 ratio and levels of inflammatory markers (sCD14 and IL-6) at later clinic visits. We present here a proof-of-concept for the use of IL-32 as a predictive biomarker for disease progression in SP subjects and identify IL-32 as a potential therapeutic target. %G English %2 https://riip.hal.science/pasteur-01351138/document %2 https://riip.hal.science/pasteur-01351138/file/srep22902.pdf %L pasteur-01351138 %U https://riip.hal.science/pasteur-01351138 %~ RIIP %~ INRS-IAF